Breaking News
Globalstar Reports Strong Sales Growth and Positive Outlook for Fiscal Year 2024
Globalstar, Inc. announced a significant 27% increase in sales for the fourth quarter of fiscal 2023, totaling $52.4 million. While...
Analyst Upgrades Carlyle Secured Lending to Neutral Rating and Raises Price Target
On February 28, 2024, analyst Melissa Wedel from JP Morgan has upgraded Carlyle Secured Lending to a Neutral rating and...
Revolutionary Weight Loss Implants by Vivani Medical A GameChanger in Obesity Treatment
Vivani Medical has recently shared exciting news regarding their latest advancements in weight loss treatments. Their preclinical data on NPM-115,...
JP Morgan Analyst Upgrades Axon Enterprise to Overweight with 330 Price Target
Analyst Paul Chung from JP Morgan has recently boosted Axon Enterprise (NASDAQ: AXON) to an Overweight rating and increased the...
BMO Capital Analyst Reaffirms Republic Services with Market Perform Rating and Raises Price Target
BMO Capital analyst Devin Dodge has reaffirmed Republic Services (NYSE:RSG) with a Market Perform rating and raised the price target...
Virios Therapeutics Advancing Antiviral Therapies for Chronic Illnesses
Virios Therapeutics, a cutting-edge biotechnology company, has just released an exciting Shareholder Letter detailing its progress and upcoming goals. The...
Polestar Secures 950 Million in Funding for Ambitious Growth Plans
Polestar has recently secured a substantial $950 million in external funding from a group of 12 international banks. This funding,...
TETRA Technologies Inc Reports Strong Financial Results and Strategic Milestones for 2023
TETRA Technologies, Inc. has just unveiled its financial results for the fourth quarter and full year of 2023, showcasing a...
Analyst Ratings and Price Targets for Viridian Therapeutics
Analyst Ratings for Viridian Therapeutics In recent months, analysts have shared a range of opinions on Viridian Therapeutics (NASDAQ: VRDN),...
Adial Pharmaceuticals Expands Intellectual Property Portfolio for AD04 Treatment of Opioid Use Disorder
Adial Pharmaceuticals has recently obtained a new US patent (number 11,905,562) for their leading investigational drug, AD04, which targets the...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
Synopsys Shares Plummet Amid Fraud Allegations and Disappointing Earnings
